Description General description A cell-permeable indolinone compound that acts as a potent, ATP site-targeting PDGFR inhibitor (IC50 = 10 nM against PDGFRβ), while affecting Flk-1/KDR/ VEGFR2, FGFR1, and EGFR only at much higher concentrations (IC50 = 0.14, 2.29, and >100 µM, respectively). Reported to selectively inhibit PDGFβ- over EGF-stimulated proliferation in EGFR-expressing NIH 3T3 cultures (IC50 = 0.11 and 21.9 µM, respectively) and exhibit much weaker potency against the proliferation of HUVEC cells upon FGF or VEGF stimulation (IC50 = 10 µM). Packaging Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Sun, L., et al. 1999. J. Med. Chem.42, 5120.